|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCNL2 |
Gene summary for CCNL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCNL2 | Gene ID | 81669 |
| Gene name | cyclin L2 | |
| Gene Alias | ANIA-6B | |
| Cytomap | 1p36.33 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96S94 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 81669 | CCNL2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.14e-08 | 5.29e-01 | 0.294 |
| 81669 | CCNL2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.14e-10 | 5.89e-01 | 0.3859 |
| 81669 | CCNL2 | A001-C-207 | Human | Colorectum | FAP | 4.15e-04 | 4.72e-01 | 0.1278 |
| 81669 | CCNL2 | A015-C-203 | Human | Colorectum | FAP | 3.62e-18 | 4.85e-01 | -0.1294 |
| 81669 | CCNL2 | A002-C-201 | Human | Colorectum | FAP | 4.98e-03 | 2.55e-01 | 0.0324 |
| 81669 | CCNL2 | A001-C-119 | Human | Colorectum | FAP | 1.94e-23 | 8.96e-01 | -0.1557 |
| 81669 | CCNL2 | A001-C-108 | Human | Colorectum | FAP | 9.38e-12 | 5.39e-01 | -0.0272 |
| 81669 | CCNL2 | A002-C-205 | Human | Colorectum | FAP | 1.09e-17 | 5.17e-01 | -0.1236 |
| 81669 | CCNL2 | A001-C-104 | Human | Colorectum | FAP | 1.33e-10 | 5.33e-01 | 0.0184 |
| 81669 | CCNL2 | A015-C-005 | Human | Colorectum | FAP | 2.03e-03 | 4.23e-01 | -0.0336 |
| 81669 | CCNL2 | A015-C-006 | Human | Colorectum | FAP | 8.17e-15 | 5.86e-01 | -0.0994 |
| 81669 | CCNL2 | A015-C-106 | Human | Colorectum | FAP | 5.62e-08 | 4.69e-01 | -0.0511 |
| 81669 | CCNL2 | A002-C-114 | Human | Colorectum | FAP | 2.88e-10 | 3.73e-01 | -0.1561 |
| 81669 | CCNL2 | A015-C-104 | Human | Colorectum | FAP | 3.77e-25 | 6.30e-01 | -0.1899 |
| 81669 | CCNL2 | A015-C-202 | Human | Colorectum | FAP | 5.67e-03 | 3.22e-01 | -0.0849 |
| 81669 | CCNL2 | A001-C-014 | Human | Colorectum | FAP | 4.74e-02 | 2.60e-01 | 0.0135 |
| 81669 | CCNL2 | A002-C-016 | Human | Colorectum | FAP | 3.50e-03 | 2.19e-02 | 0.0521 |
| 81669 | CCNL2 | A015-C-002 | Human | Colorectum | FAP | 5.58e-06 | 3.99e-01 | -0.0763 |
| 81669 | CCNL2 | A001-C-007 | Human | Colorectum | CRC | 5.94e-05 | 5.85e-01 | 0.1899 |
| 81669 | CCNL2 | A001-C-203 | Human | Colorectum | FAP | 3.60e-08 | 4.56e-01 | -0.0481 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCNL2 | SNV | Missense_Mutation | c.575N>G | p.His192Arg | p.H192R | Q96S94 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCNL2 | SNV | Missense_Mutation | novel | c.1486N>A | p.Glu496Lys | p.E496K | Q96S94 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.952) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCNL2 | insertion | Nonsense_Mutation | novel | c.1498_1499insAGGGAATCCTGACTTTTAAAATGTGAGGGACTTTTGATCCATGAGCC | p.Ser500Ter | p.S500* | Q96S94 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| CCNL2 | deletion | Frame_Shift_Del | c.696delC | p.Phe232LeufsTer47 | p.F232Lfs*47 | Q96S94 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| CCNL2 | deletion | Frame_Shift_Del | novel | c.292delG | p.Ala98ProfsTer19 | p.A98Pfs*19 | Q96S94 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CCNL2 | SNV | Missense_Mutation | novel | c.1018A>G | p.Lys340Glu | p.K340E | Q96S94 | protein_coding | tolerated(0.06) | benign(0.169) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CCNL2 | SNV | Missense_Mutation | rs779990304 | c.775C>T | p.Arg259Cys | p.R259C | Q96S94 | protein_coding | deleterious(0.02) | probably_damaging(0.98) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CCNL2 | SNV | Missense_Mutation | novel | c.332A>G | p.Tyr111Cys | p.Y111C | Q96S94 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CCNL2 | SNV | Missense_Mutation | novel | c.356N>G | p.Ser119Cys | p.S119C | Q96S94 | protein_coding | deleterious(0.01) | probably_damaging(0.946) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CCNL2 | SNV | Missense_Mutation | novel | c.883N>A | p.Glu295Lys | p.E295K | Q96S94 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |